'Hitchhiking' viral therapy deals a double blow to cancer
Scientists have shown how a promising viral therapy that delivers a double blow to cancer can sneak up on tumours undetected by hitching a ride on blood cells.
The work, led by researchers from the University of Leeds and The Institute of Cancer Research (ICR), reveals how the 'hitch-hiking' virus is shielded from antibodies in the blood stream that might otherwise neutralise its anti-cancer properties.
The findings, from a study in patients, suggest that viral therapies like this can be effectively injected into the bloodstream during routine outpatient appointments - just like standard chemotherapy agents making them potentially suitable for use against a wide range of cancers.
Reovirus is a promising new way of treating cancer that attacks the disease on two fronts. Not only does the virus kill cancer cells directly, but it also triggers an immune response - like a vaccine that helps eliminate residual cancer cells.
Many patient trials of reovirus are currently underway, including several in the UK led by the same University of Leeds and ICR scientists. Up until now, however, doctors have not been sure about the best way to deliver the experimental treatment. Although the virus can be injected directly into tumours, this is a relatively complicated procedure requiring considerable technical expertise. This delivery method also makes it difficult to treat tumours deep within the body, such as the liver, lungs, pancreas, and stomach.
Researchers had been concerned that reovirus might not reach the tumours it was supposed to treat if it was delivered intravenously, like standard chemotherapy agents are. They had expected that antibodies in the blood would mop up and neutralise the virus before it arrived at its intended target.
But now tests on a small group of patients have shown that this is not the case. In fact, not only did the virus stay active during its journey through the bloodstream but it also homed in on cancer cells, ignoring nearby healthy tissue.
University of Leeds' researcher Professor Alan Melcher, who receives funding from Cancer Research UK, jointly led the study. He said: "It seems that reovirus is even cleverer than we had thought. By piggybacking on blood cells, the virus is managing to hide from the body's natural immune response and reach its target intact. This could be hugely significant for the uptake of viral therapies like this in clinical practice."
Dr Kevin Harrington from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, who jointly led the study, said: "Viral treatments like reovirus are showing real promise in patient trials. This study gives us the very good news that it should be possible to deliver these treatments with a simple injection into the bloodstream. It would have been a significant barrier to their widespread use if they could only have been injected into the tumour, but the finding that they can hitch a ride on blood cells will potentially make them relevant to a broad range of cancers. We also confirmed that reovirus was specifically targeting cancer cells and leaving normal cells alone, which we hope should mean fewer side-effects for patients."
The study involved 10 patients with advanced bowel cancer who were due to have surgery on tumours that had spread to the liver. All patients were given up to five doses of the reovirus in the weeks before surgery as outpatients.
Blood tests carried out shortly after treatment found the active virus associated with blood cells. Samples taken later showed that the hitch-hiking virus did not overstay its welcome with the cells and was cleared quickly from the system.
When researchers looked at pieces of tissue removed during surgery up to four weeks later, they found 'viral factories' and active virus in the tumour, but not normal liver. This confirmed that the reovirus had been delivered specifically to the cancer after being injected into the bloodstream.
Dr Julie Sharp, senior science information manager at Cancer Research UK, which part-funded the research, said: "This promising study shows that reovirus can trick the body's defences to reach and kill cancer cells and suggests that it could be given to patients using a simple injection. We look forward to seeing how this research develops and if this could one day become part of standard cancer treatment."
Full details of the work are published today in the journal Science Translational Medicine.
More information: Adair, RA, "Cell Carriage, Delivery, and Selective Replication of an Onocolytic Virus in Tumor in Patients," Science Translational Medicine, 2012.
Journal reference: Science Translational Medicine
Provided by University of Leeds
- The multi-tasking reovirus Feb 08, 2007 | not rated yet | 0
- Macavity wasn't there! How absent reoviruses kill cancer Feb 21, 2011 | not rated yet | 0
- Harmless human virus may be able to boost the effects of chemotherapy Apr 03, 2012 | not rated yet | 0
- Reovirus may be a novel approach to prostate cancer treatment Mar 09, 2010 | not rated yet | 0
- Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells Apr 16, 2008 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
Older prostate cancer patients with other underlying health conditions should think twice before committing to surgery or radiation therapy for their cancer, according to a multicenter study led by researchers in the UCLA ...
Cancer 13 hours ago | not rated yet | 0 |
Intensity-modulated radiation therapy has become the most commonly used type of radiation in prostate cancer, but research from the University of North Carolina suggests that the therapy may not be more effective than older, ...
Cancer 14 hours ago | not rated yet | 0
New research suggests that a compound abundant in the Mediterranean diet takes away cancer cells' "superpower" to escape death. By altering a very specific step in gene regulation, this compound essentially re-educates cancer ...
Cancer 15 hours ago | 4.8 / 5 (13) | 2 |
(HealthDay)—For young adults needing either a chest or abdominopelvic computed tomography (CT), the short-term risk of death from underlying morbidity is greater than the long-term risk of radiation-induced ...
Cancer 16 hours ago | not rated yet | 0
In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.
Cancer 21 hours ago | not rated yet | 0 |
(Medical Xpress)—Cardiologists have identified a trio of biomarkers that may predict which patients with heart disease have a high risk of heart attack or death in the next two years.
24 minutes ago | not rated yet | 0 |
Each day, an average of nine people are killed in the United States and more than 1,000 injured by drivers doing something other than driving.
39 minutes ago | not rated yet | 0
(Medical Xpress)—We spend about a third of our life asleep, but why we need to do so remains a mystery. In a recent publication, researchers at University of Surrey and University College London suggest a new hypothesis, ...
34 minutes ago | not rated yet | 0
(Medical Xpress)—International researchers are studying the salt intake of Indian adults to provide vital new data to aid the development of a national salt reduction strategy.
24 minutes ago | not rated yet | 0
(Medical Xpress)—Exposure to sunshine as a small child is crucial to the development of a healthy eye according to results of long-term myopia study conducted by University of Sydney researchers.
14 minutes ago | not rated yet | 0
Johns Hopkins researchers say they have discovered specific chemical alterations in two genes that, when present during pregnancy, reliably predict whether a woman will develop postpartum depression.
2 hours ago | not rated yet | 0 |